LONGITUDINAL OCULAR SURVEY OF 202 FILIPINO PATIENTS WITH MULTI-BACILLARY (MB) LEPROSY TREATED WITH 2 YEAR WHO-MULTIPLE DRUG THERAPY

Jesus M Ravanes¹, Roland V Cellona¹, Marivic Balagon¹, Rodolfo M Abalos¹, Gerald P Walsh¹ and Douglas S Walsh²

¹Leonard Wood Memorial Center for Leprosy Research, Cebu, Philippines; ²US Army Medical Component, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand

Abstract. The aim of this study was to describe the ocular conditions in multi-bacillary (MB) leprosy patients treated with 2 year WHO multiple drug therapy (MDT), consisting of dapsone, clofazimine and rifampin, a regimen expected to reduce ocular complications of leprosy. We conducted comprehensive eye examinations in 202 Filipino MB leprosy patients before, during, and after WHO 2 year MDT. Assessments were carried out for at least 5 years. Inflammatory “lepra” reactions occurred in 62% (reversal reaction, 52%; erythema nodosum leprosum, 10%); most were mild. Eye abnormalities consisted mostly of diminished corneal sensitivity before MDT (6%) and lagopthalmos (n = 7, 3.4%). Six of 7 lagophthalmos cases occurred in a subset of 132 patients with facial patches (5%). Visual acuity scores, intra-ocular pressures and pupil cycle times were unremarkable. Bacillary invasion, keratitis, episcleritis, iridocyclitis, ectropion, synechiae, glaucoma and cataract formation were not detected. Scleral clofazimine pigmentation was frequent, resolving in most within 3 years of treatment cessation. Facial patches at presentation may denote a higher risk for lagophthalmos. We propose the generally low rates of ocular problems reflected mild lepra reactions, due to anti-inflammatory properties of clofazimine, a relatively young cohort, and a readily accessible community-based clinic permitting earlier diagnosis and prompt treatment.

Keywords: leprosy, lepra reactions, ocular disease, WHO multi-drug therapy (MDT)

INTRODUCTION

Leprosy, caused by Mycobacterium leprae, usually presents with skin lesions and enlarged nerves (Sehgal, 1994). Patients with multi-bacillary (MB) or disseminated leprosy, often consisting of lepromatous (LL) and borderline lepromatous (BL) leprosy, are at high risk for ocular lesions, either from inflammatory episodes called...
“lepra” reactions or, less commonly, “by direct invasion with M. leprae (Schwab, 1992; Chacko et al, 1997; Ffytche, 1998).

Two kinds of lepra reactions, reversal reaction (RR) and erythema nodosum leprosum (ENL), may cause nerve damage, leading to eye complications, that in many leprosy endemic communities, is a leading cause of visual impairment (Courtright, 1988; Ffytche, 1989; 1998; Schwab, 1992; Sundar Rao et al, 1998). Facial leprosy lesions, also called face patches, may increase the risk for ocular complications. However, the frequency of ocular morbidity varies greatly by region, and is attributed to genetic, immunologic and environmental factors, and differences in diagnostic and treatment resources (Courtright, 1988, 1998; Courtright et al, 1997).

In 1982, the World Health Organization (WHO) recommended two year multiple drug therapy (MDT), consisting of dapsone, rifampin, and clofazimine, for all patients with MB leprosy (Sehgal, 1994). Clofazimine, a drug with anti-bacterial and strong anti-inflammatory properties, is expected to reduce the incidence and severity of leprosy disabilities, including ocular complications, partly by reducing lepra reactions (Fajardo et al, 1999). Clofazimine darkens skin and sclera (Moore, 1983).

Between 1991 and 1998, a “Longitudinal Ocular Study of Leprosy” (LOSOL) was undertaken in several countries to describe ocular complications where prompt, supervised MDT is routine, with a goal of providing information to address ocular morbidity in other leprosy endemic regions (Courtright et al, 2002; Daniel et al, 2006a, b). This report describes data from Cebu, an urban setting which enrolled a relatively young cohort with ready access to a well known community-based clinic, permitting earlier diagnosis, prompt treatment monitoring and regular follow-up visits.

### MATERIALS AND METHODS

#### Study design

This was a prospective, longitudinal survey of newly diagnosed MB leprosy patients conducted at the Leonard Wood Memorial (LWM) Center for Leprosy Research. The study was approved by the LWM institutional review board. Enrolment occurred from 1989 to 1998, with study follow-up visits through 2003 (Table 1).

After signed informed consent, patients received a comprehensive pre-treatment eye examination, began 2 years of MDT, and had repeat eye examinations approximately every 6 months until treatment completion. Thereafter, examinations were conducted annually, with a goal of not less than 5 years of assessments, including 2 years during MDT. Ocular assessments included general eye examinations, visual acuity, pupil cycle

<table>
<thead>
<tr>
<th>Year</th>
<th>Number enrolled</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>12</td>
</tr>
<tr>
<td>1990</td>
<td>33</td>
</tr>
<tr>
<td>1991</td>
<td>50</td>
</tr>
<tr>
<td>1992</td>
<td>36</td>
</tr>
<tr>
<td>1993</td>
<td>19</td>
</tr>
<tr>
<td>1994</td>
<td>3</td>
</tr>
<tr>
<td>1995</td>
<td>0</td>
</tr>
<tr>
<td>1996</td>
<td>14</td>
</tr>
<tr>
<td>1997</td>
<td>30</td>
</tr>
<tr>
<td>1998</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>202</td>
</tr>
</tbody>
</table>
times, corneal sensitivity, inflammatory conditions, lagophthalmos, scleral examination for clofazimine deposition (golden brown pigmentation), and response to treatment. During this survey, incident cases of blindness related to leprosy were not expected.

MB leprosy was diagnosed by conventional slit skin smears and skin biopsies. Patients were clinically classified according to the Ridley-Jopling scale (Ridley et al., 1966). In this manner, patients with MB leprosy had a BI of ≥ 2+ from one or more of 6 standard slit skin smear sites, a logarithmic measure of the bacterial load scaled from 0 to 6 (Sehgal, 1994). A “face patch” was defined as a leprosy lesion anywhere above the neck.

All patients received a 2 year MDT regimen consisting of monthly observed rifampin and clofazimine at the clinic, and daily self-administered clofazimine and dapsone, in accordance with WHO guidelines. Treatment of all ocular conditions followed local standards of care.

To reduce loss to follow-up, field personnel assisted some patients in attending the clinic for scheduled eye examinations, and some received nominal travel costs. If a patient was diagnosed with an ocular condition requiring therapy at any time during the study, treatment was implemented in a timely fashion according to local standards of care without cost. If at any time the patient declined examination or study participation, treatment was still offered. For all nonscheduled visits with ocular complaints (self-presentation or referral), a comprehensive eye examination was conducted.

Sample size, data collection and analysis

An enrollment goal of approximately 300 patients was based on an expected complication rate of 3-10%. The expected drop out rate, based on historical trends, was 5-10%. All data were recorded on a standardized case report form, entered into a computerized database and cross checked for completeness and accuracy. The incidence of specific ocular abnormalities was tabulated in relation to demographic and clinical characteristics. Lepra reactions and ocular findings, in relation to MDT, were recorded.

RESULTS

Among 300 patients enrolled, 202 were assessed per protocol, with examinations for at least 5 years, including the two year MDT period (Table 1). Some patients enrolled earlier in the study had assessment periods extending beyond 5 years. Ninety-eight patients (33%) were classified as lost to follow-up, most citing unwillingness to comply with rigorous study requirements over a 5 year period, and the remainder due to relocation or death. All patients lost to follow-up were excluded from analysis.

Among the 202 patients assessed per protocol, 179 (89%) were < 40 years old at MB leprosy diagnosis, and the male to
Table 3
Ridley-Jopling classification and mean bacteriologic index (BI) of patients at enrollment.

<table>
<thead>
<tr>
<th>Leprosy classification</th>
<th>Number of patients (% of total)</th>
<th>Mean BI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borderline tuberculoid (BT)</td>
<td>3 (1.5%)</td>
<td>1.7</td>
</tr>
<tr>
<td>Borderline (BB)</td>
<td>1 (0.5%)</td>
<td>3.0</td>
</tr>
<tr>
<td>Borderline lepromatous (BL)</td>
<td>122 (60%)</td>
<td>3.3</td>
</tr>
<tr>
<td>Lepromatous (LL)</td>
<td>76 (38%)</td>
<td>4.4</td>
</tr>
<tr>
<td>Total</td>
<td>202</td>
<td></td>
</tr>
</tbody>
</table>

Table 4
Number of lepra reactions, during or after multiple drug therapy (MDT).

<table>
<thead>
<tr>
<th>Leprosy type (n)</th>
<th>Reversal reactions</th>
<th>ENL&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borderline tuberculoid (3)</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Borderline (1)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Borderline lepromatous (122)</td>
<td>78</td>
<td>5</td>
</tr>
<tr>
<td>Lepromatous (76)</td>
<td>27</td>
<td>14</td>
</tr>
<tr>
<td>Total</td>
<td>106 (52%)</td>
<td>20 (10%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>ENL, erythema nodosum leprosum

Table 5
Summary of 7 patients developing lagophthalmos.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Face patch</th>
<th>Reversal reaction (with skin signs)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Onset</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>L – 052</td>
<td>Yes</td>
<td>Yes</td>
<td>MDT, month 20</td>
<td>4 years</td>
</tr>
<tr>
<td>L – 064</td>
<td>No</td>
<td>No&lt;sup&gt;a&lt;/sup&gt;</td>
<td>MDT, month 19</td>
<td>4 years</td>
</tr>
<tr>
<td>L – 073</td>
<td>Yes</td>
<td>No&lt;sup&gt;a&lt;/sup&gt;</td>
<td>MDT, month 5</td>
<td>Unresolved</td>
</tr>
<tr>
<td>L – 092</td>
<td>Yes</td>
<td>No&lt;sup&gt;a&lt;/sup&gt;</td>
<td>MDT, month 21</td>
<td>2 years</td>
</tr>
<tr>
<td>L – 189</td>
<td>Yes</td>
<td>Yes</td>
<td>Pre MDT</td>
<td>Unresolved (Fig 1)</td>
</tr>
<tr>
<td>L – 195</td>
<td>Yes</td>
<td>Yes</td>
<td>MDT, month 7</td>
<td>Unresolved (Fig 2)</td>
</tr>
<tr>
<td>L – 263</td>
<td>Yes</td>
<td>Yes</td>
<td>MDT, month 17</td>
<td>6 months</td>
</tr>
<tr>
<td>Total</td>
<td>6/7 (86%)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4/7 (57%)</td>
<td>6 during MDT</td>
<td>4 resolved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 pre MDT</td>
<td>3 unresolved</td>
</tr>
</tbody>
</table>

MDT, multiple drug therapy
<sup>a</sup>Lagophthalmos alone can be a sign of reversal reaction, suggesting face patches are a better determinant.
<sup>b</sup>6 of 7 lagophthalmos incidents occurred in a subset of 132 patients with face patches (5%).
Nearly all 202 patients (98%) were classified as borderline lepromatous or lepromatous, the 2 most disseminated forms of leprosy (Table 3).

Table 4 shows the type and number of lepra reactions that occurred at least once in any individual patient during MDT and follow-up, with 106 (52%) developing RR and 20 (10%) developing ENL. Seventy-six patients had no reactions. All reactions were mild or moderate in severity (little or no interference with daily activities) and, for skin and nerve signs, responded to oral corticosteroids.

At enrollment, diminished corneal sensitivity was present in 6% of patients, all normalizing during MDT. Intra-ocular pressures were unremarkable, ranging from 10-18 mmHg throughout the survey (normal 10-20 mmHg). For adnexal involvement, 5 patients exhibited muscle weakness before MDT; 4 normalized after completion of MDT. For pupil cycle times (normal ≤ 2 ms), before MDT, 5 patients (2.5%) had abnormal values. After MDT completion and during follow-up, 2 of 5 remained abnormal. There were no detectable trends between abnormal pupil cycle times and age, gender, treatment status or pupil size.

As summarized in Table 5, lagophthalmos was noted in 7 patients, 1 on enrollment and 6 developing during MDT. Six lagophthalmos incidents (5%) occurred in the subset of 132 patients with face patches, versus 1 in 70 patients (1.5%) without face patches.
More than half of the lagophthalmos incidents (4/7) occurred in patients who also developed “classic” reversal reaction at some point, to include new skin lesions, a distinction made because lagophthalmos alone, without skin lesions, can be a sign of reversal reaction. There were no incidents of lagophthalmos in any patient that developed ENL. All patients with lagophthalmos were treated with oral corticosteroids: 4 resolved fully and 3 remained unresolved at last study exam (Figs 1-2).

Approximately 70% of patients developed asymptomatic ocular clofazimine pigmentation, most within 12 months of starting MDT, primarily near the limbus (Fig 3). In most, the deposits disappeared within 3 years of treatment cessation.

Bacillary invasion with *M. leprae*, keratitis, episcleritis, iridocyclitis, ectropion, synchiae, premature glaucoma and cataract formation were not detected in any patient.

**DISCUSSION**

As worldwide implementation of MDT for MB leprosy began in 1982, with an expected reduction in overall morbidity, including ocular complications, regional surveys like this may provide critical information. In our cohort, ocular abnormalities were relatively infrequent and mild. Lagophthalmos was the most significant problem, occurring in 3.4% of the entire cohort, and clofazimine pigmentation of the sclera, a reversible, non-pathogenic side effect, was noted in most patients. Notably, 6 of 7 lagophthalmos incidents occurred among a subset of 132 patients with face patches (about 5%), some eventually developing reversal.
reaction, suggesting face patches denote a higher risk population. However, we propose the overall low rate of ocular complications reflect a low frequency of lepra reactions, likely due to the anti-inflammatory properties of clofazimine, potent anti-bacterial properties of MDT, relatively young patients, and availability of a well established, accessible clinic permitting earlier diagnosis and prompt supervised treatment.

In many communities, stigma from clofazimine pigmentation may lead to treatment default, especially if supervision is unavailable. Here, rigorous monthly observation of drug administration, per WHO guidelines, insured therapeutic levels of clofazimine (1/2 life 70 days), even if self treatment adherence was poor. MDT has greatly reduced leprosy prevalence and patients needing lifelong care now outnumber those on therapy, changing the focus of leprosy management (Lewallen, 1997; Hogeweg, 1998a, b). To maintain the risk-benefit profile of MDT, disability prevention, in including ocular complications, is important (Lewallen et al, 2007).

Lepra reactions, often considered the most important risk factor for ocular complications, are difficult to monitor and require prompt anti-inflammatory treatment to prevent irreversible damage (Schwab, 1992). In many regions, ocular pathology associated with reactions is poorly addressed (Chacko et al, 1997). In untreated leprosy patients, the natural history of ocular complications is complex and multi-factorial (Schwab, 1992; Job et al, 1998; Sundar Rao et al, 1998). In our survey, reactions were generally mild and promptly treated, factors that likely contributed to the low rate of ocular problems.

Leprosy is not distributed randomly and the clinical characteristics of disease, including ocular involvement, vary by region (Courtright et al, 1997). This variability generally prohibits extrapolation of data from one community to another, highlighting the importance of conducting studies in distinct geographic locations such as Cebu. Sufficient incidence, capability for long term follow-up, adequate infrastructure, ophthalmology services, and a well managed MDT program, all present in Cebu, are critical factors in accurate reporting. As eye pathology may progress after MDT completion, ocular exams should be conducted for a period of at least 5 years after diagnosis (Samanta and Das, 2007).

The data collected in Cebu underscore the value of early detection of leprosy, prompt initiation of supervised MDT per WHO guidelines, monitoring for and treatment of lepra reactions, and the important role of ophthalmology services in addressing and mitigating leprosy-related ocular morbidity.

ACKNOWLEDGEMENTS

The World Health Organization and The American Leprosy Missions, Greenville, South Carolina, USA, provided financial support. We thank Paul Courtright, MD, Sundar Rao, MD, and Ebenezzer Daniel, MD for support. Rico Abella, Mary Grace Ares, and Junie Abellana provided clinical assistance. Guillerma Lim and Pris Reed provided administrative support.

REFERENCES


Hogeweg M. Strategies for improvement of management of ocular complications in leprosy. *Indian J Lepr* 1998a; 70: 61-70.

Hogeweg M. Strategies for improvement of management of ocular complications in leprosy. *Indian J Lepr* 1998b; 70: 61-70.


Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. *Int J Lepr Other Mycobact Dis* 1966; 34: 255-73.

Samanta SK, Das D. Recent advances in ocular leprosy. *Indian J Lepr* 1997; 70: 61-70.

